Generic placeholder image

Infectious Disorders - Drug Targets

Author(s): Esmaeil Mehraeen, Omid Dadras, Amir Masoud Afsahi, Amirali Karimi, Mehrzad Mohsseni Pour, Pegah Mirzapour, Alireza Barzegary, Farzane Behnezhad, Pedram Habibi, Mohammad Amin Salehi, Farzin Vahedi, Mohammad Heydari, Shaghayegh Kianzad, Banafsheh Moradmand-Badie, Mohammad Javaherian, SeyedAhmad SeyedAlinaghi* and Jean-Marc Sabatier

DOI: 10.2174/1871526521666210923144837

DownloadDownload PDF Flyer Cite As
Vaccines for COVID-19: A Systematic Review of Feasibility and Effectiveness

Article ID: e230921196758 Pages: 14

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Introduction: Many potential vaccines for COVID-19 are being studied and developed. Several studies have reported on the safety and efficacy of these vaccines. This systematic review aimed to report on the current evidence concerning the feasibility and effectiveness of vaccines for COVID-19.

Methods: A systematic search was carried out utilizing the keywords in the online databases, including Scopus, Web of Science, PubMed, Embase, and Cochrane. We included both human and non-human studies because of the vaccine novelty, limiting our ability to include sufficient human studies.

Results: This review showed several SARS-CoV-2 vaccines to be currently under development using different platforms, including eight vaccines that are adenovirus-based vectors, six vaccines that are RNA-based formulations, one vaccine being DNA-based formulation, and other vaccines using other platforms, including lipid nanoparticles. Although the safety and efficacy profiles of these vaccines are still under debate, some countries have allowed for emergency use of some vaccines in at-risk populations, such as healthcare workers and the elderly.

Conclusion: It is crucial to gather as much clinically relevant evidence as possible regarding the immunogenicity, efficacy, and safety profiles of available vaccines and adhere wisely to CDC protocols and guidelines for vaccine production.

Keywords: Vaccine, effectiveness, feasibility, treatment, immunity, diagnosis, therapy, COVID-19, SARS-CoV-2.

Graphical Abstract

[1]
Mehraeen E, Karimi A, Barzegary A, et al. Predictors of mortality in patients with COVID-19-a systematic review. Eur J Integr Med 2020; 40: 101226.
[http://dx.doi.org/10.1016/j.eujim.2020.101226] [PMID: 33101547]
[2]
Sekhavati E, Jafari F, SeyedAlinaghi S, et al. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. Int J Antimicrob Agents 2020; 56(4): 106143.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.106143] [PMID: 32853672]
[3]
SeyedAlinaghi S, Ghadimi M, Hajiabdolbaghi M, et al. Prevalence of COVID-19-like symptoms among people living with HIV, and using antiretroviral therapy for prevention and treatment. Curr HIV Res 2020; 18(5): 373-80.
[http://dx.doi.org/10.2174/1570162X18666200712175535] [PMID: 32652912]
[4]
Mehraeen E, Behnezhad F, Salehi MA, Noori T, Harandi H. SeyedAlinaghi S. Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence. Eur Arch Otorhinolaryngol 2021; 278(2): 307-12. Epub 2020 Jun 17.
[http://dx.doi.org/10.1007/s00405-020-06120-6.] [PMID: 32556781]
[5]
Chauhan G, Madou MJ, Kalra S, Chopra V, Ghosh D, Martinez-Chapa SO. Nanotechnology for COVID-19: Therapeutics and vaccine research. ACS Nano 2020; 14(7): 7760-82.
[http://dx.doi.org/10.1021/acsnano.0c04006] [PMID: 32571007]
[6]
Wu SC. Progress and concept for COVID‐19 vaccine development. Biotechnol J 2020; 15(6): e2000147.
[http://dx.doi.org/10.1002/biot.202000147] [PMID: 32304139]
[7]
Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet 2020; 395(10223): 514-23.
[http://dx.doi.org/10.1016/S0140-6736(20)30154-9 ] [PMID: 31986261 ]
[8]
Ghiasvand F, Ghadimi M, Ghadimi F, Safarpour S, Hosseinzadeh R. SeyedAlinaghi S. Symmetrical polyneuropathy in coronavirus disease 2019 (COVID-19). IDCases 2020; 21: e00815.
[http://dx.doi.org/10.1016/j.idcr.2020.e00815] [PMID: 32514394 ]
[9]
Ghiasvand F, Miandoab SZ, Harandi H, Golestan FS, Alinaghi SA. A patient with COVID-19 disease in a Referral Hospital in Iran: a typical case. Infect Disord Drug Targets 2020; 20(4): 559-62.
[10]
Ghiasvand F. SeyedAlinaghi S. Isolated Anosmia as a Presentation of COVID-19: An Experience in a Referral Hospital. Infect Disord Drug Targets 2020; 20(3): 350.
[http://dx.doi.org/10.2174/1871526520999200520173216 ] [PMID: 32436835]
[11]
Sadr S, SeyedAlinaghi S, Ghiasvand F, et al. Isolated severe thrombocytopenia in a patient with COVID-19: A case report. IDCases 2020; 21: e00820.
[http://dx.doi.org/10.1016/j.idcr.2020.e00820] [PMID: 32483524]
[12]
Rothan HA, Byrareddy SNJ. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020; 109: 102433.
[13]
Wong SH, Lui RN, Sung J. Covid‐19 and the digestive system. J Gastroenterol Hepatol 2020; 35(5): 344-8.
[14]
Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L. Kidney impairment is associated with in-hospital death of COVID-19 patients. MedRxiv 2020.
[http://dx.doi.org/10.1101/2020.02.18.20023242]
[15]
Zhang C, Shi L. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020; 5(5): 428-30.
[16]
Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie XJNRC. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020; 17(5): 259-60.
[17]
Padron-Regalado EJId. Vaccines for SARS-CoV-2: Lessons from other coronavirus strains. Infect Dis Ther 2020; 9: 255-74.
[18]
Asadollahi-Amin A, Hasibi M, Ghadimi F, Rezaei H. SeyedAlinaghi S. Lung involvement found on chest CT scan in a pre-symptomatic person with sars-cov-2 infection: A Case report. Trop Med Infect Dis 2020; 5(2): E56.
[http://dx.doi.org/10.3390/tropicalmed5020056] [PMID: 32272630]
[19]
Ahmadinejad Z, Salahshour F, Dadras O, Rezaei H. SeyedAlinaghi S. Pleural effusion as a sign of coronavirus disease 2019 (COVID-19) pneumonia: a case report. Infect Disord Drug Targets 2021; 21(3): 468-72.
[http://dx.doi.org/10.2174/1871526520666200609125045] [PMID: 32516107]
[20]
Mehraeen E, Seyed Alinaghi SA, Nowroozi A, et al. A systematic review of ECG findings in patients with COVID-19. Indian Heart J 2020; 72(6): 500-7.
[http://dx.doi.org/10.1016/j.ihj.2020.11.007] [PMID: 33357637]
[21]
Koyama T, Weeraratne D, Snowdon JL, Parida LJP. Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment 2020; 9(5): 324.
[http://dx.doi.org/10.3390/pathogens9050324]
[22]
Chauhan G, Madou MJ, Kalra S, Chopra V, Ghosh D, Martinez-Chapa SOJAn. Nanotechnology for COVID-19: Therapeutics and vaccine research 2020; 14(7): 7760-82.
[23]
Bertram S, Glowacka I, Müller MA, Lavender H, Gnirss K, Nehlmeier I, et al. Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease 2011; 85(24): 13363-72.
[http://dx.doi.org/10.1128/JVI.05300-11]
[24]
Wu SCJBJ. Progress and concept for COVID‐19 vaccine development 2020.
[25]
Al-Amri SS, Abbas AT, Siddiq LA, et al. Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein. Sci Rep 2017; 7(1): 44875.
[http://dx.doi.org/10.1038/srep44875] [PMID: 28332568]
[26]
Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol 2009; 7(3): 226-36.
[http://dx.doi.org/10.1038/nrmicro2090] [PMID: 19198616]
[27]
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020; 38(1): 1-9.
[PMID: 32105090]
[28]
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation 2020; 367(6483): 1260-3.
[29]
Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody 2020; 9(1): 382-5.
[http://dx.doi.org/10.1080/22221751.2020.1729069]
[30]
Smith TRF, Patel A, Ramos S, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun 2020; 11(1): 2601.
[http://dx.doi.org/10.1038/s41467-020-16505-0] [PMID: 32433465]
[31]
Agrawal AS, Tao X, Algaissi A, et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother 2016; 12(9): 2351-6.
[http://dx.doi.org/10.1080/21645515.2016.1177688] [PMID: 27269431]
[32]
He Y, Zhou Y, Wu H, et al. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol 2004; 173(6): 4050-7.
[http://dx.doi.org/10.4049/jimmunol.173.6.4050] [PMID: 15356154]
[33]
Tseng C-T, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 2012; 7(4): e35421.
[http://dx.doi.org/10.1371/journal.pone.0035421] [PMID: 22536382]
[34]
Escobar LE, Molina-Cruz A, Barillas-Mury CJPotNAoS. BCG vaccine protection from severe coronavirus disease 2019 (COVID19) 2020; 117(30): 17720-6.
[35]
Sharquie I. BCG is a good immunotherapeutic agent for viral and autoimmune diseases: Is it a new weapon against coronavirus (COVID-19)? Electron J Gen Med 2020; 17(6): em229.
[36]
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383(27): 2603-15.
[http://dx.doi.org/10.1056/NEJMoa2034577] [PMID: 33301246]
[37]
Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol 2020; 11: 585354.
[http://dx.doi.org/10.3389/fimmu.2020.585354] [PMID: 33163000]
[38]
Al-Kofahi M, Jacobson P, Boulware DR, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID‐19: The desperate search for effectiveness. Clin Pharmacol Ther 2020; 108(4): 766-9.
[http://dx.doi.org/10.1002/cpt.1874] [PMID: 32344449]
[39]
Andreani J, Le Bideau M, Duflot I, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog 2020; 145: 104228.
[http://dx.doi.org/10.1016/j.micpath.2020.104228] [PMID: 32344177]
[40]
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 In vitro. Antiviral Res 2020; 178: 104787.
[http://dx.doi.org/10.1016/j.antiviral.2020.104787] [PMID: 32251768]
[41]
Asai A, Konno M, Ozaki M, et al. COVID-19 drug discovery using intensive approaches. Int J Mol Sci 2020; 21(8): 2839.
[http://dx.doi.org/10.3390/ijms21082839] [PMID: 32325767]
[42]
Siddiqui AJ, Jahan S, Ashraf SA, et al. Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2. J Biomol Struct Dyn 2020; 1-14.
[http://dx.doi.org/10.1080/07391102.2020.1802345] [PMID: 32752944 ]
[43]
Siddiqui AJ, Danciu C, Ashraf SA, et al. Plants-derived biomolecules as potent antiviral phytomedicines: New insights on ethnobotanical evidences against coronaviruses. Plants 2020; 9(9): 1244.
[http://dx.doi.org/10.3390/plants9091244] [PMID: 32967179]
[44]
Reddy MN, Adnan M, Alreshidi MM, Saeed M, Patel M. Evaluation of anticancer, antibacterial and antioxidant properties of a medicinally treasured fern tectaria coadunata with its phytoconstituents analysis by HR-LCMS. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 2020; 20(15): 885-56.
[http://dx.doi.org/10.2174/1871520620666200318101938]
[45]
Ganjhu RK, Mudgal PP, Maity H, et al. Herbal plants and plant preparations as remedial approach for viral diseases. Virusdisease 2015; 26(4): 225-36.
[http://dx.doi.org/10.1007/s13337-015-0276-6] [PMID: 26645032]
[46]
Ben-Shabat S, Yarmolinsky L, Porat D, Dahan A. Antiviral effect of phytochemicals from medicinal plants: Applications and drug delivery strategies. Drug Deliv Transl Res 2020; 10(2): 354-67.
[http://dx.doi.org/10.1007/s13346-019-00691-6] [PMID: 31788762]
[47]
An X, Martinez-Paniagua M, Rezvan A, Fathi M, Singh S, Biswas S, et al. Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2 bioRxiv 2020.
[48]
Case JB, Rothlauf PW, Chen RE, et al. Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice. Cell Host Microbe 2020; 28(3): 465-474.e4.
[http://dx.doi.org/10.1016/j.chom.2020.07.018] [PMID: 32798445]
[49]
Chiuppesi F, Salazar MDA, Contreras H, Nguyen V, Martinez J, Park S, et al. Development of a multi-antigenic SARS-CoV-2 vaccine using a synthetic poxvirus platform. 2020.
[http://dx.doi.org/10.21203/rs.3.rs-40198/v1]
[50]
Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 2020; 586(7830): 567-71.
[http://dx.doi.org/10.1038/s41586-020-2622-0] [PMID: 32756549]
[51]
Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med 2020; 383(16): 1544-55.
[http://dx.doi.org/10.1056/NEJMoa2024671] [PMID: 32722908]
[52]
Dai L, Zheng T, Xu K, et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 2020; 182(3): 722-733.e11.
[http://dx.doi.org/10.1016/j.cell.2020.06.035] [PMID: 32645327]
[53]
Erasmus JH, Khandhar AP, O’Connor MA, et al. An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci Transl Med 2020; 12(555): eabc9396.
[http://dx.doi.org/10.1126/scitranslmed.abc9396] [PMID: 32690628]
[54]
Feng L, Wang Q, Shan C, et al. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nat Commun 2020; 11(1): 4207.
[http://dx.doi.org/10.1038/s41467-020-18077-5] [PMID: 32826924]
[55]
Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396(10249): 467-78.
[http://dx.doi.org/10.1016/S0140-6736(20)31604-4] [PMID: 32702298]
[56]
Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020; 369(6499): 77-81.
[http://dx.doi.org/10.1126/science.abc1932] [PMID: 32376603]
[57]
Graham SP, McLean RK, Spencer AJ, et al. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. NPJ Vaccines 2020; 5(1): 69.
[http://dx.doi.org/10.1038/s41541-020-00221-3] [PMID: 32793398]
[58]
Gu H, Chen Q, Yang G, et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science 2020; 369(6511): 1603-7.
[http://dx.doi.org/10.1126/science.abc4730] [PMID: 32732280]
[59]
Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med 2020; 383(20): 1920-31.
[http://dx.doi.org/10.1056/NEJMoa2022483] [PMID: 32663912]
[60]
Keech C, Albert G, Cho I, et al. Phase 1-2 Trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 2020; 383(24): 2320-32.
[http://dx.doi.org/10.1056/NEJMoa2026920] [PMID: 32877576]
[61]
Laczkó D, Hogan MJ, Toulmin SA, et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in Mice. Immunity 2020; 53(4): 724-732.e7.
[http://dx.doi.org/10.1016/j.immuni.2020.07.019] [PMID: 32783919]
[62]
McKay PF, Hu K, Blakney AK, et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat Commun 2020; 11(1): 3523.
[http://dx.doi.org/10.1038/s41467-020-17409-9] [PMID: 32647131]
[63]
Mercado NB, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 2020; 586(7830): 583-8.
[http://dx.doi.org/10.1038/s41586-020-2607-z] [PMID: 32731257]
[64]
Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020; 586(7830): 589-93.
[http://dx.doi.org/10.1038/s41586-020-2639-4] [PMID: 32785213]
[65]
Powell AE, Zhang K, Sanyal M, Tang S, Weidenbacher PA, Li S, et al. A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice. bioRxiv 2020.
[66]
Qi X, Ke B, Feng Q, et al. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection. Chem Commun (Camb) 2020; 56(61): 8683-6.
[http://dx.doi.org/10.1039/D0CC03263H] [PMID: 32613971]
[67]
Rohaim MA, Munir M. A scalable topical vectored vaccine candidate against SARS-CoV-2. Vaccines (Basel) 2020; 8(3): E472.
[http://dx.doi.org/10.3390/vaccines8030472] [PMID: 32846910]
[68]
Sun W, Leist SR, McCroskery S, Liu Y, Slamanig S, Oliva J, et al. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate. bioRxiv 2020.
[http://dx.doi.org/10.1101/2020.07.26.221861]
[69]
Tostanoski LH, Wegmann F, Martinot AJ, et al. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nat Med 2020; 26(11): 1694-700.
[http://dx.doi.org/10.1038/s41591-020-1070-6] [PMID: 32884153]
[70]
van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 2020; 586(7830): 578-82.
[http://dx.doi.org/10.1038/s41586-020-2608-y] [PMID: 32731258]
[71]
Walsh EE, Frenck R, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study medRxiv 2020.
[http://dx.doi.org/10.1101/2020.08.17.20176651]
[72]
Wang H, Zhang Y, Huang B, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against sars-cov-2. Cell 2020; 182(3): 713-721.e9.
[http://dx.doi.org/10.1016/j.cell.2020.06.008] [PMID: 32778225]
[73]
Wang Y, Wang L, Cao H, Liu C. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen. J Med Virol 2020.
[PMID: 32691875]
[74]
Wu S, Zhong G, Zhang J, et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun 2020; 11(1): 4081.
[http://dx.doi.org/10.1038/s41467-020-17972-1] [PMID: 32796842]
[75]
Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials. JAMA 2020; 324(10): 951-60.
[http://dx.doi.org/10.1001/jama.2020.15543] [PMID: 32789505 ]
[76]
Yang J, Wang W, Chen Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 2020; 586(7830): 572-7.
[http://dx.doi.org/10.1038/s41586-020-2599-8] [PMID: 32726802]
[77]
Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 2020; 369(6505): 806-11.
[http://dx.doi.org/10.1126/science.abc6284] [PMID: 32434945]
[78]
Zhang NN, Li XF, Deng YQ, et al. A thermostable mRNA vaccine against COVID-19. Cell 2020; 182(5): 1271-83.e16.
[http://dx.doi.org/10.1016/j.cell.2020.07.024.] [PMID: 32795413]
[79]
Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 396(10249): 479-88.
[http://dx.doi.org/10.1016/S0140-6736(20)31605-6] [PMID: 32702299]
[80]
Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020; 395(10240): 1845-54.
[http://dx.doi.org/10.1016/S0140-6736(20)31208-3] [PMID: 32450106]
[81]
Ura TOK, Shimada M. Developments in Viral Vector-Based Vaccines. Vaccines (Basel) 2014; 624-41.
[82]
Le Tung Thanh AZ. Kumar Arun, Román Raúl Gómez, Tollefsen AZ, Saville Melanie, Mayhew Stephen. The COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020; 19(5): 305-6.
[83]
Cuiling Zhang GM, Shan Hu, Li Junwei. Advances in mRNA vaccines for infectious diseases 2020; 594
[http://dx.doi.org/10.3389/fimmu.2019.00594]
[84]
Ning Wang JS, Jiang Shibo. Du Lanying. Subunit vaccines against emerging pathogenic human coronaviruses. Frontiers in Microbiology 2020.
[http://dx.doi.org/10.3389/fmicb.2020.00298]
[85]
Hobernik D. BMDV-. How far from clinical use? Int J Mol Sci 2018; 3605: 2018.
[http://dx.doi.org/10.3390/ijms19113605] [PMID: 30445702]
[86]
Izda V, Jeffries MA, Sawalha AH. COVID-19: A review of therapeutic strategies and vaccine candidates. Clin Immunol 2021; 222: 108634.
[http://dx.doi.org/10.1016/j.clim.2020.108634] [PMID: 33217545]
[87]
Belete TM. Review on up-to-date status of candidate vaccines for COVID-19 disease. Infect Drug Resist 2021; 14: 151-61.
[http://dx.doi.org/10.2147/IDR.S288877] [PMID: 33500636]
[88]
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Lancet 2021; S0140-6736(21): 00234-8.